Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mohammadreza Ahi
Observed names:
Ahi, Mohammadreza,
Mohammad Reza Ahi
Institution:
Shahid Sadoughi University of Medical Sciences and Health Services
Observed institutions:
Iran University of Medical Sciences,
Shahid Chamran University of Ahvaz,
Shahid Sadoughi University of Medical Sciences and Health Services
ORCID:
0000-0003-2600-5515
Observed ORCID:
0000-0003-2600-5515
OpenAlex ID:
A5078014361
A Serological Survey on Antibodies against Akabane Virus in Sheep in Southwest of Iran
2015
·
Mohammad Reza Ahi
, mahdi Pourmahdi Borujeni
, et al.
·
Iranian Journal of Virology
·
15
PDF
Metrical analysis of dromedary digital bones
2014
·
Jamal Nourinezhad
, Yazdan Mazaheri
, et al.
·
Anatomical Science International
·
11
Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial
2022
·
Mohammadreza Ahi
, Ramin Hamidi Farahani
, et al.
·
Vaccines
·
7
PDF
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
2023
·
Fatemeh Gholami
, Ramin Hamidi Farahani
, et al.
·
BMC Infectious Diseases
·
4
PDF
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial
2023
·
Masoud Solaymani-Dodaran
, Pouria Basiri
, et al.
·
Virology Journal
·
2
PDF
The Prognostic Value of Residual Gensini Score on 1-Year Cardiac Mortality in Patients Undergoing Percutaneous Coronary Intervention
2026
·
Mohammad Reza Ahi
, Abbas Andishmand
, et al.
·
The Journal of Tehran University Heart Center
·
1
Comparison of postoperative complications following CABG in diabetic and non-diabetic patients.
2026
·
Akram Ghadiri-Anari
, Farnaz Bemaninejad
, et al.
·
PubMed Central
PDF
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial
2023
·
Akram Ansarifar
, Ramin Hamidi Farahani
, et al.
·
Vaccine X
Show more works
View as search
Works count:
13
Citation count:
40
H-index:
4
I10-index:
2
Year
Topic
Type